Trial · NCT01777412
Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations
NCT01777412, Phase 1, Completed, Johns Hopkins University; results first posted 2015-05-29
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations. Trials, record NCT01777412. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01777412
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations
- NCT number
- NCT01777412
- Status
- Completed
- Phases
- Phase 1
- Enrollment
- 10 participants, actual
- Lead sponsor
- Johns Hopkins University
- Conditions
- Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
- Interventions
- Bevacizumab
- First posted
- 2013-01-28
- Last updated
- 2015-08-21
- Results first posted
- 2015-05-29
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Baseline Expanded Disability Status Score (EDSS) | Admission to hospital | EDSS The EDSS provides a total score on a scale that ranges from 0 to 10. The first levels 1.0 to 4.5 refer to people with a high degree of ambulatory ability and the subsequent levels 5.0 to 9.5 refer to the loss of ambulatory ability. |
| Primary | Safety Assessment and Side Effects | 91 days | Frequency and severity of adverse events and side effects. Serious adverse events are considered those which are life threatening, lead to hospitalization and related to the drug. Side effects are considered minor effects of the experimental drug that do not significantly impact the care of the patient with the experimental drug. |
| Primary | Follow-Up Expanded Disability Status Score (EDSS) | Follow-up visit 91 days after admission | EDSS The EDSS provides a total score on a scale that ranges from 0 to 10. The first levels 1.0 to 4.5 refer to people with a high degree of ambulatory ability and the subsequent levels 5.0 to 9.5 refer to the loss of ambulatory ability. |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Baseline Expanded Disability Status Score (EDSS) | Admission to hospital | units on a scale | MEDIAN | |
| PRIMARY | Safety Assessment and Side Effects | 91 days | participants | NUMBER | |
| PRIMARY | Follow-Up Expanded Disability Status Score (EDSS) | Follow-up visit 91 days after admission | units on a scale | MEDIAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Baseline Expanded Disability Status Score (EDSS) | Bevacizumab | 3.5 | Inter-Quartile Range 2.0 to 7.0 | units on a scale | |
| Safety Assessment and Side Effects | Bevacizumab | Serious Adverse Event: Hospitalization | 1 | participants | |
| Safety Assessment and Side Effects | Bevacizumab | Side Effects | 0 | participants | |
| Follow-Up Expanded Disability Status Score (EDSS) | Bevacizumab | 3.0 | Inter-Quartile Range 1.75 to 6.5 | units on a scale |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Bevacizumab | 10 | |
| Overall Study | COMPLETED | Bevacizumab | 10 | |
| Overall Study | NOT COMPLETED | Bevacizumab | 0 |
Source ClinicalTrials.gov
Adverse events2
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Headache | Nervous system disorders | Bevacizumab | 1 | 10 | 1 |
| serious | Hospitalization for Urinary Tract Infection | Infections and infestations | Bevacizumab | 1 | 10 | 1 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Bevacizumab | ||
| Total, other adverse events | Bevacizumab | 1 | 10 |
| Total, serious adverse events | Bevacizumab | 1 | 10 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01777412
GET https://conductscience.org/api/trials/v1/NCT01777412/registered